Medicine and Dentistry
Durvalumab
100%
Progression Free Survival
54%
Radiation Therapy
36%
Adverse Event
27%
Disease Exacerbation
27%
Survival Rate
27%
Lung Cancer
27%
Distant Metastasis
18%
Stage 3
18%
Body Weight
9%
Antibody
9%
Ligand
9%
Overall Survival
9%
Platinum
9%
Hazard Ratio
9%
Pneumonia
9%
Interim Analysis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Durvalumab
100%
Progression Free Survival
54%
Adverse Event
27%
Disease Exacerbation
27%
Lung Cancer
27%
Survival Rate
27%
Distant Metastasis
18%
Ligand
9%
Antibody
9%
Platinum
9%
Overall Survival
9%
Pneumonia
9%
Agricultural and Biological Sciences
Survival Rate
100%
Confidence Interval
100%
Body Weight
33%
Antibodies
33%